κ阿片受体激动剂的拟精神病效应。 - Suppr

Psychotomimetic effects of kappa opioid receptor agonists.

作者信息

White Kate L, Roth Bryan L

机构信息

Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7365, USA.

出版信息

Biol Psychiatry. 2012 Nov 15;72(10):797-8. doi: 10.1016/j.biopsych.2012.08.014.

DOI:10.1016/j.biopsych.2012.08.014

PMID:23083945

Abstract

摘要

相似文献

Psychotomimetic effects of kappa opioid receptor agonists.

Biol Psychiatry. 2012 Nov 15;72(10):797-8. doi: 10.1016/j.biopsych.2012.08.014.

Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.

Ann N Y Acad Sci. 2004 Oct;1025:404-13. doi: 10.1196/annals.1316.050.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. doi: 10.1124/jpet.107.129023. Epub 2007 Oct 19.

Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):184-90. doi: 10.1016/j.ejphar.2015.07.018. Epub 2015 Jul 8.

Kappa opioids as potential treatments for stimulant dependence.

AAPS J. 2005 Oct 19;7(3):E592-9. doi: 10.1208/aapsj070361.

Cognition: the ultimate brain function.

Neuropsychopharmacology. 2011 Jan;36(1):1-2. doi: 10.1038/npp.2010.171.

The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?

Neuropsychopharmacology. 2009 Jan;34(1):247. doi: 10.1038/npp.2008.165.

Melatonin MT receptor as a novel target in neuropsychopharmacology: MT ligands, pathophysiological and therapeutic implications, and perspectives.

Pharmacol Res. 2019 Jun;144:343-356. doi: 10.1016/j.phrs.2019.04.015. Epub 2019 Apr 25.

Kappa-opioid ligands in the study and treatment of mood disorders.

Pharmacol Ther. 2009 Sep;123(3):334-43. doi: 10.1016/j.pharmthera.2009.05.008. Epub 2009 Jun 2.

The therapeutic potential of κ-opioids for treatment of pain and addiction.

Neuropsychopharmacology. 2011 Jan;36(1):369-70. doi: 10.1038/npp.2010.137.

引用本文的文献

Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?

Neuronal Signal. 2018 May 14;2(2):NS20170145. doi: 10.1042/NS20170145. eCollection 2018 Jun.

Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.

Pharmacol Rep. 2020 Feb;72(1):24-35. doi: 10.1007/s43440-019-00014-z. Epub 2019 Dec 20.

Biased signalling: from simple switches to allosteric microprocessors.

Nat Rev Drug Discov. 2018 Apr;17(4):243-260. doi: 10.1038/nrd.2017.229. Epub 2018 Jan 5.

Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Transl Perioper Pain Med. 2016;1(2):4-16.

Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Curr Neuropharmacol. 2016;14(2):165-76. doi: 10.2174/1570159x13666150727220944.

Identification of novel functionally selective κ-opioid receptor scaffolds.

Mol Pharmacol. 2014 Jan;85(1):83-90. doi: 10.1124/mol.113.089649. Epub 2013 Oct 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Psychotomimetic effects of kappa opioid receptor agonists.

Biol Psychiatry. 2012 Nov 15;72(10):797-8. doi: 10.1016/j.biopsych.2012.08.014.

Possible pharmacotherapy of the opioid kappa receptor agonist for drug dependence.

Ann N Y Acad Sci. 2004 Oct;1025:404-13. doi: 10.1196/annals.1316.050.

N-methylacetamide analog of salvinorin A: a highly potent and selective kappa-opioid receptor agonist with oral efficacy.

J Pharmacol Exp Ther. 2008 Jan;324(1):188-95. doi: 10.1124/jpet.107.129023. Epub 2007 Oct 19.

Biased agonism at kappa opioid receptors: Implication in pain and mood disorders.

Eur J Pharmacol. 2015 Sep 15;763(Pt B):184-90. doi: 10.1016/j.ejphar.2015.07.018. Epub 2015 Jul 8.

Kappa opioids as potential treatments for stimulant dependence.

AAPS J. 2005 Oct 19;7(3):E592-9. doi: 10.1208/aapsj070361.

Cognition: the ultimate brain function.

Neuropsychopharmacology. 2011 Jan;36(1):1-2. doi: 10.1038/npp.2010.171.

The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?

Neuropsychopharmacology. 2009 Jan;34(1):247. doi: 10.1038/npp.2008.165.

Melatonin MT receptor as a novel target in neuropsychopharmacology: MT ligands, pathophysiological and therapeutic implications, and perspectives.

Pharmacol Res. 2019 Jun;144:343-356. doi: 10.1016/j.phrs.2019.04.015. Epub 2019 Apr 25.

Kappa-opioid ligands in the study and treatment of mood disorders.

Pharmacol Ther. 2009 Sep;123(3):334-43. doi: 10.1016/j.pharmthera.2009.05.008. Epub 2009 Jun 2.

The therapeutic potential of κ-opioids for treatment of pain and addiction.

Neuropsychopharmacology. 2011 Jan;36(1):369-70. doi: 10.1038/npp.2010.137.

引用本文的文献

Targeting opioid receptor signaling in depression: do we need selective κ opioid receptor antagonists?

Neuronal Signal. 2018 May 14;2(2):NS20170145. doi: 10.1042/NS20170145. eCollection 2018 Jun.

Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.

Pharmacol Rep. 2020 Feb;72(1):24-35. doi: 10.1007/s43440-019-00014-z. Epub 2019 Dec 20.

Biased signalling: from simple switches to allosteric microprocessors.

Nat Rev Drug Discov. 2018 Apr;17(4):243-260. doi: 10.1038/nrd.2017.229. Epub 2018 Jan 5.

Major Depressive Disorder and Kappa Opioid Receptor Antagonists.

Transl Perioper Pain Med. 2016;1(2):4-16.

Kappa Opioids, Salvinorin A and Major Depressive Disorder.

Curr Neuropharmacol. 2016;14(2):165-76. doi: 10.2174/1570159x13666150727220944.

Identification of novel functionally selective κ-opioid receptor scaffolds.

Mol Pharmacol. 2014 Jan;85(1):83-90. doi: 10.1124/mol.113.089649. Epub 2013 Oct 10.

Psychotomimetic effects of kappa opioid receptor agonists.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献